KIT and mastocytosis: The pivotal clinical study in mastocytosis that led to drug approval for this indication was a single-arm, phase 2 trial in 89 patients with ASM (n=16), SM-AHN (n=57) or MCL (n=16), mostly carrying the D816V KIT mutation (Gotlib et al., 2016).